Drug intelligence / Profile preview

anti-midkine antibody

Development stage: Preclinical
Lead developer: Anagenics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

This drug is a humanized monoclonal antibody developed by Cellmid in collaboration with Antitope. It targets midkine and is being developed for the treatment of inflammatory and autoimmune disorders. The antibody was humanized using Antitope's proprietary Composite Human Antibody™ technology to ensure it is non-immunogenic, and Antitope was also responsible for producing sufficient quantities for preclinical testing using their high-yielding CHO expression system.

Targets

MDK (Midkine)

Beyond the preview

Go deeper on anti-midkine antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-midkine antibody.

Explore the full profile